Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) shares traded up 6.7% on Thursday. The stock traded as high as $0.4289 and last traded at $0.4289. Approximately 117 shares were traded during trading, a decline of 98% from the average session volume of 6,508 shares. The stock had previously closed at $0.4019.
Avenue Therapeutics Price Performance
The company has a 50 day simple moving average of $0.47 and a 200-day simple moving average of $0.36. The stock has a market capitalization of $1.41 million, a P/E ratio of 0.02 and a beta of -0.32.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapies for acute pain. The company has concentrated primarily on hospital-based treatments, with the goal of addressing pain management needs while offering alternatives to conventional opioid therapies.
Avenue’s lead product candidate is intravenous (IV) tramadol, an investigational formulation of tramadol hydrochloride intended for the management of acute postoperative pain in adults who require an intravenous analgesic.
Further Reading
- Five stocks we like better than Avenue Therapeutics
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
